In Review: Discussions on HB 398 and HB 399 (prior authorization) continue as stakeholders work toward consolidating overlapping prior authorization proposals into a single bill legislative approach, both bills are scheduled for hearings on February 20. Testimony will focus on the clinical value of prior authorization, advocating for medical management safeguards over unnecessary administrative burdens. Additionally, SB 317 (prior authorization) remains a concern due to its impact on FDA drug shortages, PCMA and member companies are actively meeting with legislative leadership, coordinating data and testimony to reinforce the necessity of prior authorization in ensuring patient safety, cost containment, and appropriate medication use.

If you have any questions, please contact Tonia Sorrell-Neal at tsorrell-neal@pcmanet.org.